Bio-Gene Technology Ltd (BGT) — Cash Flow-to-Debt Ratio
Bio-Gene Technology Ltd (BGT) has a Cash Flow-to-Debt Ratio of -3.08x as of December 2025, meaning its operating cash flow of AU$-946.61K could theoretically repay -3% of its total liabilities (AU$307.71K) in one year. See free cash flow generation of Bio-Gene Technology Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bio-Gene Technology Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Bio-Gene Technology Ltd across 11 annual periods. Also explore Bio-Gene Technology Ltd (BGT) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Bio-Gene Technology Ltd (2014–2025)
Year-by-year debt coverage analysis for Bio-Gene Technology Ltd. For market capitalisation and broader financial context, see Bio-Gene Technology Ltd (BGT) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.86x | AU$-2.54 Million | AU$522.98K | ▲ +35.0% |
| 2024 | -7.48x | AU$-2.75 Million | AU$368.45K | ▼ -40.1% |
| 2023 | -5.34x | AU$-3.28 Million | AU$613.88K | ▼ -12790.3% |
| 2022 | 0.04x | AU$43.52K | AU$1.03 Million | ▲ +101.7% |
| 2021 | -2.42x | AU$-1.83 Million | AU$754.57K | ▲ +16.6% |
| 2020 | -2.90x | AU$-1.64 Million | AU$567.29K | ▲ +19.2% |
| 2019 | -3.59x | AU$-2.20 Million | AU$613.61K | ▼ -14.8% |
| 2018 | -3.12x | AU$-2.37 Million | AU$759.59K | ▼ -60.2% |
| 2017 | -1.95x | AU$-729.15K | AU$373.94K | ▼ -78.1% |
| 2016 | -1.09x | AU$-419.35K | AU$383.00K | ▲ +97.8% |
| 2014 | -49.81x | AU$-47.57K | AU$955.00 | — |